Source comparison
IGF-1 LR3 Muscle Growth Results Timeline Comparison
The following table compares igf-1 lr3 muscle growth results timeline expect against other anabolic research compounds researchers commonly evaluate. IGF-1 LR3 (40–80mcg/day) IGF-1 receptor agonist, mTOR activation 3–4 weeks 5–8 weeks Downregulation after 8–10
This comparison does not assign a generated winner or score.
- The following table compares igf-1 lr3 muscle growth results timeline expect against other anabolic research compounds researchers commonly evaluate.
- IGF-1 LR3 (40–80mcg/day)
- IGF-1 receptor agonist, mTOR activation
- 3–4 weeks
- 5–8 weeks
- Downregulation after 8–10 weeks
- Most rapid visible results, requires cycling to maintain efficacy
- MK-677 (25mg/day)
- Growth hormone secretagogue
- 6–8 weeks
- 12–16 weeks
- Minimal. Works via endogenous GH pulses
- Slower onset but sustainable long-term without cycling
- GHRP-2 (100mcg 3x/day)
- Ghrelin receptor agonist
- 4–6 weeks
- 8–12 weeks
- Tolerance develops to GH release magnitude
- Requires multiple daily dosing, less convenient than IGF-1 LR3
- Native IGF-1 (40mcg/day)
- IGF-1 receptor agonist
- 5–7 weeks
- 10–14 weeks
- None. But IGFBP binding limits bioavailability
- Comparable mechanism to LR3 but hampered by 10-minute half-life
- Testosterone (200mg/week)
- Androgen receptor agonist
- 8–16 weeks
- None in normal dose ranges
- Gold standard for hypertrophy but carries androgenic side effects IGF-1 LR3 lacks
- IGF-1 LR3 occupies a unique position: fastest visible onset among peptide-based compounds, but requires strategic cycling to prevent receptor desensitization. Researchers seeking sustained anabolic effects beyond 12 weeks typically transition to MK-677 during IGF-1 LR3 washout periods to maintain elevated growth factor signalling without overlapping receptor pathways.